SCHEMBL24974727

SCHEMBL24974727

CCCn1cc(-c2cccc(-c3cnc(N4CCC5(CC4)NC(=O)N(Cc4ccccc4)C5=O)nc3)c2)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.40
▸ TACR1 P25103 1/20 0.39
▸ CDC7 O00311 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ GSK3B P49841 3/20 0.37
▸ ROCK2 O75116 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ GSK3A P49840 2/20 0.37
▸ SGK2 Q9HBY8 2/20 0.37
▸ DYRK3 O43781 1/20 0.37
▸ CLK2 P49760 1/20 0.37
▸ CSNK1G2 P78368 1/20 0.37
▸ PRKG1 Q13976 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ CSNK1G1 Q9HCP0 1/20 0.37
▸ CSNK1G3 Q9Y6M4 1/20 0.37
▸ HDAC3 O15379 6/20 0.37
▸ HDAC4 P56524 6/20 0.37
▸ HDAC1 Q13547 6/20 0.37
▸ HDAC7 Q8WUI4 6/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24974594 0.80 KMT2A (0.41) KMT2ATACR1CDC7MEN1GSK3B
SCHEMBL24974736 0.80 TACR1 (0.51) KMT2ATACR1CDC7GSK3BROCK2
SCHEMBL24974552 0.78 KMT2A (0.35) KMT2ATACR1CDC7MEN1GSK3B
SCHEMBL24974605 0.77 TACR1 (0.49) KMT2ATACR1MEN1GSK3BROCK2
SCHEMBL24974747 0.76 DYRK3 (0.36) KMT2ATACR1GSK3BROCK2MAPK1
SCHEMBL24974734 0.75 NAMPT (0.54) KMT2ATACR1CDC7GSK3BROCK2
SCHEMBL24974785 0.71 KMT2A (0.38) KMT2ATACR1CDC7MEN1MAPK1
SCHEMBL24974731 0.70 HDAC6 (0.48) KMT2ATACR1HDAC3HDAC1HDAC2
SCHEMBL24974591 0.70 TACR1 (0.40) KMT2ATACR1MEN1GSK3BROCK2
SCHEMBL21150836 0.68 DYRK3 (0.33) KMT2ATACR1GSK3BROCK2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B KMT2A 499/4885TACR1 76/4885CDC7 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback